Liposome-mediated intraperitoneal interleukin 10 gene transfer increases survival in cecal litigation and puncture model of sepsis

Shock

Volumn 26, Issue 1, 2006, Pages 37-40

  Kabay, Burhan ^a   Kocaefe, Y Cetin ^a   Baykal, Atac ^a   Ozguc, Meral ^a   Sayek, Iskender ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cecal ligation and puncture; Gene transfer; IL 10; Liposome mediated gene transfer; Sepsis

Indexed keywords

LIPOSOME; RECOMBINANT INTERLEUKIN 10; IL10 PROTEIN, HUMAN; INTERLEUKIN 10; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM; GENE EXPRESSION; GENE TRANSFER; MORTALITY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; SEPSIS; SURVIVAL; TRANSGENE; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMPARATIVE STUDY; DISEASE MODEL; GENE THERAPY; GENETICS; HUMAN;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-10; LIPOSOMES; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SEPSIS;

EID: 33747174582     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000215316.14489.e5     Document Type: Article

References (25)

1. Beutler B, Rietschel ET: Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 3:169-176, 2003.
2. Sayek I: Animal models for intra-abdominal infection. Hepatogastroenterology 44:923-926, 1997.
3. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
4. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, Holzmann B, Stier A, Pfeffer K, Heidecke CD: Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock 21:505-511, 2004.
5. Pinsky MR: Dysregulation of the immune response in severe sepsis. Am J Med Sci 328:220-229, 2004.
6. Deitch EA: Animal models of sepsis and shock: a review and lessons learned. Shock 9:1-11, 1998.
7. Remick DG: Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 9:75-82, 2003.
8. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T: Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547-550, 1993.
9. Clarke CJ, Hales A, Hunt A, Foxwell BM: IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol 28:1719-1726, 1998.
10. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik AB, Kierulf P: Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 184:51-60, 1996.
11. Berg DJ, Kuhn R, Rajewsky K, Muller W, Menon S, Davidson N, Grunig G, Rennick D: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96:2339-2347, 1995.
12. Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 30:S58-S63, 2002.
13. Fuchs AC, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Radwanski E, Affrime MB, et al.: Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol 16:291-303, 1996.
14. Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime MB, Cutler DL: Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 87:699-705, 1996.
15. Kumar A, Zanotti S, Bunnell G, Habet K, Anel R, Neumann A, Cheang M, Dinarello CA, Cutler D, Parrillo JE: Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response. Crit Care Med 33:331-340, 2005.
16. Templeton NS: Cationic liposome-mediated gene delivery in vivo. Biosci Rep 22:283-295, 2002.
17. Itano H, Mora BN, Zhang W, Ritter JH, McCarthy TJ, Yew NS, Mohanakumar T, Patterson GA: Lipid-mediated ex vivo gene transfer of viral interleukin 10 in rat lung allotransplantation. J Thorac Cardiovasc Surg 122:29-38, 2001.
18. Minter RM, Ferry MA, Murday ME, Tannahill CL, Bahjat FR, Oberholzer C, Oberholzer A, LaFace D, Hutchins B, Wen S, et al.: Adenoviral delivery of human and viral IL-10 in murine sepsis. J Immunol 167:1053-1059, 2001.
19. Oberholzer A, Oberholzer C, Efron PA, Scumpia PO, Uchida T, Bahjat K, Ungaro R, Tannahill CL, Murday M, Bahjat FR, et al.: Functional modification of dendritic cells with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis. Shock 23:507-515, 2005.
20. Sakhuja K, Reddy PS, Ganesh S, Cantaniag F, Pattison S, Limbach P, Kayda DB, Kadan MJ, Kaleko M, Connelly S: Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 14:243-254, 2003.
21. Latifi SQ, O'Riordan MA, Levine AD: Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 70:4441-4446, 2002.
22. Song GY, Chung CS, Chaudry IH, Ayala A: What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery 126:378-383, 1999.
23. Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B: Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J Immunol 169:384-392, 2002.
24. Schneider CP, Schwacha MG, Chaudry IH: The role of interleukin-10 in the regulation of the systemic inflammatory response following trauma-hemorrhage. Biochim Biophys Acta 1689:22-32, 2004.
25. Oberholzer A, Souza SM, Tschoeke SK, Oberholzer C, Abouhamze A, Pribble JP, Moldawer LL: Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 23:488-493, 2005.